$1.41
-0.21(-13.27%)
Mkt Cap $79M
$0.44
$4.23
52-Week Range
At a Glance
AI-generatedDeepening net losses and accelerated cash burn marked FY2025 as TuHURA advanced its clinical pipeline amid the Kineta acquisition, with management highlighting risks from unproven operating assumptions and ongoing negative cash flows.
8-K
TuHURA Biosciences reported its 2025 financial results, highlighting increased R&D spending and net cash outflows, while providing updates on clinical trial progress and upcoming milestones across its immuno-oncology pipeline.$79M
Market Cap
—
Revenue
-$33M
Net Income
Employees19
Fundamentals
How The Business Makes Money
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001498382
ISINUS8989201038
Address10500 University Center Drive, Tampa, US
SEC EDGAR